

          -  Hypersensitivity to chloroquine or hydroxychloroquine

          -  History of retinal disease (macular degeneration, diabetic retinopathy, retinal
             rear/detachment, retinitis pigmentosa)

          -  History of seizure disorder

          -  History of ventricular tachycardia/fibrillation, history of long-QT syndrome, or ICD

          -  Current creatinine clearance <10 ml/min or on hemodialysis (as evidenced in EMR)

          -  Known G6PD deficiency

          -  Current use of the following medications: digoxin, amiodarone, flecainide,
             procainamide, oral dapsone. If other meds of concern, route to pharmacist to evaluate

          -  Concomitant use of the following only at Pharmacist/Investigator discretion:
             Abiraterone acetate, agalsidase, conivaptan, dabrafenib, dacomitinib, dapsone
             (systemic), digoxin, enzalutamide, fexinidazole, flecainide, fusidic acid (systemic),
             idelalisib, mifepristone, mitotane, pimozide, amiodarone, digoxin, procainamide,
             propafenone, stiripentol

          -  Currently on hospice

          -  Women of childbearing potential must not be pregnant, and must avoid becoming pregnant
             while on treatment and for 30 days following treatment discontinuation. Men must avoid
             fathering a child while on treatment and for 30 days following treatment
             discontinuation

          -  Any clinical factors such as bleeding, active infection, or psychiatric factors that
             in the judgment of the investigator would preclude safe participation and compliance
             with study procedures.
      